Search

Changes to Formulary as of 18th July 2017:

BNF Category Number

Product/indication

Detail of change

8.2.4

Daclizumab

Added as a RED drug and added link to NICE TA441

13.5.3

Ixekizumab

Added as a RED drug and added link to NICE TA442

1.9.1

Obeticholic acid

Added as a RED drug and added link to NICE TA443

10.1.3

Certolizumab and secukinumab

Added link to NICE TA445

1

n/a

Added link to CG61

4

n/a

Added link to CG100

4.2.3, 4.8.1 and 4.7.4.2

Valproate and developmental disorders: new alert asking for patient review and further consideration of risk minimisation measures

Added link to MHRA DSU guidance

8.2.4

Fingolimod - Multiple sclerosis therapies: signal of rebound effect after stopping or switching therapy

Added link to MHRA DSU guidance

2.8.1

Epoprostenol - Flolan (epoprostenol): reminder of replacement of Flolan (with Solvent pH 10.5) with Flolan (with Solvent pH 12)

Added link to MHRA DSU guidance

9.5.5

Selenium

Added as a RED drug

4.5.1

Liraglutide (Saxenda)

Added as NOT REVIEWED

6.7

Strontium

Deleted from formulary as product discontinued

4.8.1

Retigabine

Deleted from formulary as product discontinued

7.3

Contraceptives

Wording of section updated and now states to use most cost-effective choice in each sub type of contraceptive.